Nephronophthisis-related ciliopathies(NPHP-RC)represent one of the most common causes of chronic kidney disease in the first three decades of life and are characterized by a broad genetic and clinical heterogeneity.1 ...
详细信息
Nephronophthisis-related ciliopathies(NPHP-RC)represent one of the most common causes of chronic kidney disease in the first three decades of life and are characterized by a broad genetic and clinical heterogeneity.1 To date,more than 90 genes have been identified that cause autosomalrecessive NPHP-RC if mutated,accounting for up to 60%of cases.1 Among these,homozygous deletions of NPHP1 are the most common *** genes localize to primary cilia,basal bodies,or the centrosome and lead to a primary ciliary disruption if mutated,thereby causing a broad phenotypical spectrum.1 Patients that suffer from NPHP-RC can either have an isolated renal phenotype,such as polyuria,polydipsia,decreased urinary concentration ability,and secondary enuresis due to loss of tubular function,or present with extrarenal symptoms including retinal degeneration,cerebellar vermis hypoplasia,or hepatic *** are often diagnosed in early adolescence,reaching end-stage renal disease before 25 years of age,but early onset and rapidly progressive forms of NPHP-RC also exist.1 Renal ultrasound indicates kidneys of normal or reduced renal length with increased echogenicity and corticomedullary cysts.
BACKGROUND Although it is well established that coronavirus disease 2019(COVID-19)is associated with inflammation and a prothrombotic state leading to stroke and venous thromboembolism(VTE),the nuances of this associa...
详细信息
BACKGROUND Although it is well established that coronavirus disease 2019(COVID-19)is associated with inflammation and a prothrombotic state leading to stroke and venous thromboembolism(VTE),the nuances of this association are yet to be uncovered[1].Many studies link elevations in inflammatory markers to cases of *** reports of thromboembolism associated with COVID-19 occur in the venous circulation during or just after the initial hospitalization due to COVID-19[2].It is unclear how long the hypercoagulable effect of COVID-19 *** SUMMARY We present a unique case of a 65-year-old-female who presented to her primary care doctor with a sore throat,cough,fatigue,congestion,diarrhea,headache,and *** tested positive for severe acute respiratory syndrome coronavirus 2 and received a bamlanivimab infusion 9 days *** recovering from the acute illness,she received the Pfizer-BioNTech COVID-19 *** later,she presented to the Emergency Department(ED)complaining of right sided shoulder pain and motor weakness in her left hand while trying to type on a *** presentation to the ED,her calculated Padua prediction score for risk of VTE was two and inflammatory markers were not *** was found to have a brachiocephalic artery occlusion as well as an ischemic stroke which was treated with *** This case suggests hypercoagulability due to COVID-19 may extend further than current literature suggests,to at least six months.
暂无评论